NCE development supported through all development stages:

Innovative drug development requires complementary technologies:

Future drug discovery will greately benefit from the progress in computational capacities, nano- as well as imaging, that all will merge with established drug discovery platforms to create content and value for all stakeholders in health care

InnVentis has generated a focussed competence network with leaders in their fields: The accessible know-how and technologies have been centered along the development chain for small molecule enzyme inhibitors. This way InnVentis would generate an innovative "conveyor belt" model for the identification of small molecule drugs against hydroxysteroid dehydrogenase and related targets. This target focus also allows testing of lead candidates against a variety of SDR/HSDs and secures highest currenly acchievable target selectivity; in light of the emerging appreciation of polypharmacology as a major challenge for drug development, the InnVentis target focus optimally exploits cutting-edge technologies and limits the risk for later stage failure due to off-target effects. Furthermore, the target focus allows an opportunistic project development model addressing the increasing identification of new indications for validet targets as well as the rapid generation of NCEs for newly validated targets. InnVentis aims to accompany a lead through all preclinical development stages while anticipating the challenges of later clinical development; i.e. InnVentis early discovery programs address the pressing demand for biomarkers similarly like the increasing requirement of safety data beyond classic ADMETox analysis. The latter process is facilitated by the immense knowledge on physiological steroid hormone actions, which allows interpolation of anticipated effects from existing data.

A similar approach will secure continuity with respect to all targets being persued at InnVentis.

InnVentis aims not only identify NCEs, biomarkers but to the secure the following steps as a project moves on by using established networks of experts in each and every stept of drug development.